Table 3.
Anticancer activity of different concentrations of native proteins, chitosan–milk protein nanocomposite and curcumin-loaded milk protein nanoparticles against HepG2 cell lines.
| Treatments | Anticancer Activity %/Concentrations (mg/mL) | Mean | ||
|---|---|---|---|---|
| 2.5 | 5 | 10 | ||
| Chitosan | 34.97 ± 1.03 | 73.35 ± 2.25 | 91.79 ± 1.96 | 66.70 ± 1.75 |
| Curcumin | 54.06 ± 1.94 | 81.08 ± 2.32 | 95.07 ± 2.93 | 76.74 ± 2.40 |
| SC | 33.71 ± 1.29 | 71.33 ± 2.12 | 93.05 ± 2.95 | 66.03 ± 2.12 |
| CS/SCNPs | 40.4±3.35 | 82.95±3.35 | 95.29±1.71 | 72.88±2.80 |
| Cur-Cs/SCNPs | 46.49±2.64 | 86.36±2.64 | 97.31±2.04 | 76.72±2.44 |
| α-La | 36.75±1.75 | 70.70±2.40 | 92.04±1.36 | 66.50±1.84 |
| CS/α-LaNPs | 38.23±1.77 | 76.67 ± 1.43 | 94.11 ± 1.89 | 69.67 ± 1.70 |
| Cur-Cs/α-La NPs | 45.9 ± 1.40 | 81.79 ± 1.19 | 96.80 ± 3.30 | 74.83 ± 1.96 |
| βlg | 17.55 ± 2.55 | 48.36 ± 4.64 | 83.58 ± 2.42 | 49.83 ± 3.20 |
| CS/βlgNPs | 40.88 ± 2.12 | 70.84 ± 2.56 | 92.55 ± 2.45 | 68.09 ± 2.38 |
| Cur-Cs/βlg NPs | 43.27 ± 1.73 | 85.54 ± 1.37 | 95.80 ± 2.20 | 74.87 ± 1.77 |
| WPI | 18.59 ± 1.41 | 53.91 ± 1.19 | 76.64 ± 1.66 | 49.71 ± 1.42 |
| CS/WPINPs | 43.03 ± 1.53 | 81.69 ± 1.91 | 93.81 ± 1.19 | 72.84 ± 1.54 |
| Cur-Cs/WPINPs | 49.9 ± 1.10 | 82.20 ± 2.79 | 96.31 ± 2.81 | 76.14 ± 2.23 |
| WPC | 30.63 ± 2.37 | 81.29 ± 3.71 | 93.68 ± 2.18 | 68.53 ± 2.75 |
| Cs/WPC NPs | 42.74 ± 2.26 | 82.53 ± 1.07 | 95.27 ± 3.23 | 73.51 ± 2.19 |
| Cur-Cs/WPCNPs | 48.68 ± 4.32 | 80.36 ± 3.06 | 98.07 ± 3.07 | 75.70 ± 3.48 |
| Mean | 39.16 ± 2.03 | 75.94 ± 2.35 | 93.01 ± 2.31 | |
L.S.D. value at 0.05: concentrations: 0.69, treatments: 1.63, interaction: 2.83.